Monte Rosa Therapeutics (GLUE) Competitors $6.33 -0.60 (-8.66%) Closing price 04:00 PM EasternExtended Trading$6.36 +0.04 (+0.55%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. GPCR, CALT, TRVI, ELVN, TLRY, LENZ, NUVB, WVE, MAZE, and AMLXShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Structure Therapeutics (GPCR), Calliditas Therapeutics AB (publ) (CALT), Trevi Therapeutics (TRVI), Enliven Therapeutics (ELVN), Tilray Brands (TLRY), LENZ Therapeutics (LENZ), Nuvation Bio (NUVB), WAVE Life Sciences (WVE), Maze Therapeutics (MAZE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors Structure Therapeutics Calliditas Therapeutics AB (publ) Trevi Therapeutics Enliven Therapeutics Tilray Brands LENZ Therapeutics Nuvation Bio WAVE Life Sciences Maze Therapeutics Amylyx Pharmaceuticals Structure Therapeutics (NASDAQ:GPCR) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Does the media refer more to GPCR or GLUE? In the previous week, Monte Rosa Therapeutics had 17 more articles in the media than Structure Therapeutics. MarketBeat recorded 21 mentions for Monte Rosa Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.95 beat Monte Rosa Therapeutics' score of 0.30 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend GPCR or GLUE? Structure Therapeutics currently has a consensus target price of $75.71, suggesting a potential upside of 221.10%. Monte Rosa Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 142.23%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable earnings and valuation, GPCR or GLUE? Monte Rosa Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-22.46Monte Rosa Therapeutics$75.62M5.17-$72.70M$0.3617.58 Do insiders and institutionals hold more shares of GPCR or GLUE? 91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GPCR or GLUE more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Structure Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Monte Rosa Therapeutics 13.58%9.95%6.42% Which has more volatility & risk, GPCR or GLUE? Structure Therapeutics has a beta of -1.88, suggesting that its stock price is 288% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. SummaryMonte Rosa Therapeutics beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$427.99M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio17.5820.5276.4826.75Price / Sales5.17446.54531.95124.23Price / CashN/A46.0037.9261.55Price / Book1.749.6613.726.40Net Income-$72.70M-$53.02M$3.29B$271.62M7 Day Performance31.60%1.09%1.03%2.85%1 Month Performance43.86%7.93%6.32%9.64%1 Year Performance1.28%10.48%81.16%31.62% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.6941 of 5 stars$6.33-8.7%$15.33+142.2%+16.5%$427.99M$75.62M17.5890Positive NewsAnalyst RevisionGPCRStructure Therapeutics3.3028 of 5 stars$20.880.0%$75.71+262.6%-39.3%$1.20BN/A-19.89136CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180TRVITrevi Therapeutics2.8183 of 5 stars$9.75+1.4%$21.75+123.1%+150.4%$1.19BN/A-23.2120Positive NewsHigh Trading VolumeELVNEnliven Therapeutics2.672 of 5 stars$19.92+3.6%$41.20+106.8%-8.5%$1.18BN/A-9.9650News CoveragePositive NewsTLRYTilray Brands3.0121 of 5 stars$1.06-2.8%$1.94+82.8%-30.0%$1.17B$821.31M-0.462,842LENZLENZ Therapeutics1.2409 of 5 stars$40.81-2.2%$49.60+21.5%+93.9%$1.16B$5M-21.48110News CoverageNUVBNuvation Bio3.1847 of 5 stars$3.35+0.9%$7.50+123.9%+9.0%$1.15B$7.87M-5.3260News CoverageAnalyst ForecastWVEWAVE Life Sciences4.3695 of 5 stars$7.16-3.1%$20.33+184.0%+27.2%$1.14B$108.30M-7.96240MAZEMaze Therapeutics3.5062 of 5 stars$24.80+54.8%$26.33+6.2%N/A$1.09B$167.50M0.00121Analyst ForecastInsider TradeHigh Trading VolumeAMLXAmylyx Pharmaceuticals1.9997 of 5 stars$11.84+0.1%$12.25+3.5%+360.1%$1.06B-$249K-4.74200Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies GPCR Alternatives CALT Alternatives TRVI Alternatives ELVN Alternatives TLRY Alternatives LENZ Alternatives NUVB Alternatives WVE Alternatives MAZE Alternatives AMLX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLUE Stock Alerts